Table 3. Clinical efficacy outcomes in octogenarian patients after treatment with EGFR TKI (OCTOMUT study).

	N = 114
Best clinical response, n (%)
Complete response (CR)	4 (3.7)
Partial response (PR)	65 (59.6)
Stable disease (SD)	17 (15.6)
Progressive disease (PD)	14 (12.8)
Not evaluated	9 (8.3)
MD	5
Overall response rate (ORR), n (%) a	69 (63.3)
Disease control rate n (%) b	86 (78.9)
Overall survival (months), median (95% CI)	20.9 (14.3–27.1)
Progression-free survival (months), median (95% CI)	11.9 (8.6–14.7)
Other line of treatment after progression, n (%)	36/95 (37.9)

MD, missing data

^a ORR = CR + PR

^b Disease control rate = CR + PR + SD.